1. Home
  2. LEXX

LEXX

Lexaria Bioscience Corp.

Logo Lexaria Bioscience Corp.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-15-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.

Founded: 2004 Country:
Canada
Canada
Employees: N/A City: KELOWNA
Market Cap: 37.5M IPO Year: N/A
Target Price: $12.00 AVG Volume (30 days): 491.4K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.68 EPS Growth: N/A
52 Week Low/High: $0.65 - $6.85 Next Earning Date: 04-09-2024
Revenue: $385,995 Revenue Growth: 17.46%
Revenue Growth (this year): 117.11% Revenue Growth (next year): 102.49%

Share on Social Networks: